|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
Pre-market 13:59:06 | |||
| 57.29 USD | +28.25% |
|
56.56 | -1.27% |
| 12:46pm | Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy | FW |
| 11:25am | Genmab: Positive developments priced in; time to take profits |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 64.14B | |||||
| 55.53B | |||||
| 53.03B | |||||
| 45.99B | |||||
| 42.45B |
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
